Navilife

Navilife is a South Korean biotechnology company focused on the development of exosome-based liquid biopsy diagnostics and therapeutic solutions. The company utilizes its proprietary "Exo-Navi" platform to isolate high-purity exosomes from liquid samples, enabling the detection of early-stage cancer biomarkers with high sensitivity. Navilife's primary pipeline includes diagnostic tools for lung and pancreatic cancers, as well as research into exosome-mediated drug delivery systems. By leveraging exosomal protein and miRNA analysis, the company aims to provide non-invasive, accurate monitoring for oncology patients and improve survival rates through early detection.